稳心颗粒经AMPK/SIRT1/PGC-1α通路调节能量代谢并改善Cx43
该研究在心肌梗死后心力衰竭大鼠模型中观察稳心颗粒的作用,发现其通过激活AMPK/SIRT1/PGC-1α信号通路改善能量代谢并提升Cx43功能,同时提高室颤阈值,提示其多靶点调控心力衰竭能量代谢紊乱并保护Cx43。
要点
- 稳心颗粒可激活AMPK/SIRT1/PGC-1α通路,改善心衰后能量代谢。
- 稳心颗粒通过上调SIRT1对PGC-1α的正调控,促进线粒体氧化磷酸化。
- 稳心颗粒改善Cx43功能并提高室颤阈值,降低致心律失常易感性。
核心结论
- 稳心颗粒对心肌梗死后心力衰竭的能量代谢紊乱发挥多靶点调控作用,并保护Cx43,其核心机制为激活AMPK/SIRT1/PGC-1α信号通路及其下游调控网络。
研究设计与样本
- 研究采用左前降支冠状动脉结扎建立心肌梗死后心力衰竭大鼠模型,4周后以超声心动图、HE染色和Masson三色染色评估心脏功能。
主要发现
- 稳心颗粒激活AMPK/SIRT1/PGC-1α信号通路,改善心肌梗死后心力衰竭大鼠的能量代谢和Cx43功能。
- 稳心颗粒刺激SIRT1/PGC-1α轴,促进PGC-1α与PPARs和ERRs的相互作用。
- 稳心颗粒通过上调AMPK磷酸化增强SIRT1对PGC-1α的正调控,进一步激活AMPK/SIRT1/PGC-1α通路并形成正反馈环路。
- 稳心颗粒针对心力衰竭后脂肪酸氧化和葡萄糖利用的双重损伤,恢复线粒体氧化磷酸化并通过TCA循环增加ATP生成。
- 研究诱导室颤以测定室颤阈值,反映致心律失常易感性。
临床怎么用
- 稳心颗粒作为临床可用的中成药,用于防治心力衰竭相关心律失常,其机制涉及调控能量代谢和保护Cx43。
局限性
- 心力衰竭后的病理改变复杂,稳心颗粒治疗心力衰竭的潜在机制仍需进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Research has underscored the significance of targeting energy metabolic remodeling in heart failure (HF) as a crucial therapeutic avenue in recent years. Following the onset of heart failure, dysregulated energy metabolism induces multiple adverse effects, exemplified by the reduced expression of connexin 43 (Cx43)-a gap junction protein requiring substantial ATP for phosphorylation modification-in rats with post-myocardial infarction (MI) heart failure. In this study, we report that Wenxin Keli (also known as Wenxin granule), a clinically available Chinese patent medicine used for preventing and treating heart failure-related arrhythmias, modulates energy metabolism and improves Cx43 function by activating AMPK/SIRT1/PGC-1α signaling pathway. However, the pathological alterations after heart failure are intricate, and the underlying mechanism through which Wenxin Keli exerts its therapeutic effect on heart failure remains to be further elucidated. METHODS: A post-myocardial infarction heart failure rat model was established via left anterior descending coronary artery ligation. Cardiac function was evaluated 4 weeks later using echocardiography, HE, and Masson trichrome staining. ELISA was employed to detect energy metabolism-related indices, while WB analysis was used to quantify the expression levels of proteins, including SIRT1, PGC-1α, and Cx43. IHC was further utilized to assess Cx43 protein content in tissue sections. Ventricular fibrillation (VF) was induced to determine the VF threshold, providing insights into arrhythmogenic susceptibility. RESULTS: Wenxin Keli enhances energy metabolism and improves Cx43 function in post-MI heart failure rats by activating the AMPK/SIRT1/PGC-1α signaling pathway. Specifically, Wenxin Keli stimulates the SIRT1/PGC-1α axis, promoting interaction between PGC-1α and PPARs and ERRs. This dual mechanism addresses the combined impairments in fatty acid oxidation and glucose utilization after heart failure, restoring mitochondrial oxidative phosphorylation and increasing ATP production through the TCA cycle. Furthermore, Wenxin Keli boosts the positive regulatory effect of SIRT1 on PGC-1α by upregulating AMPK phosphorylation, thereby further activating the AMPK/SIRT1/PGC-1α signaling pathway and creating a positive feedback loop. CONCLUSION: Wenxin Keli exhibits multi-target regulation of energy metabolic disorders in post-myocardial infarction heart failure while protecting Cx43. Its core mechanism is activating the AMPK/SIRT1/PGC-1α signalling pathway and its downstream regulatory network.
引用
- Cui X, Lou L, Nie B, et al. Wenxin Keli regulates energy metabolism and improves Cx43 via the AMPK/SIRT1/PGC-1α pathway. Front Pharmacol. 2025. PMID: 40994651. doi:10.3389/fphar.2025.1624595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。